GHRP-6 FAQ: common questions answered
A peptide studied in growth hormone tests and an experimental stroke combination.
Also called: Growth hormone-releasing hexapeptide, SKF-110679.
Growth hormone secretagogues (ghrelin receptor) · Ghrelin receptor agonist and growth hormone secretagogue.
- Is GHRP-6 FDA-approved? No FDA-approved product or dose label found; no approval for physique or performance use.
- How do people take it? Under the skin, three times daily. Source: reported by users, not an established dose.
- What's the difference between GHRP-6 and Sermorelin? GHRP-6: a peptide studied in growth hormone tests and an experimental stroke combination. Sermorelin: an experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits. Why people pair them: a clinician-published triple combination raised IGF-1.
- Can I take it with Sermorelin with GHRP-2? A clinician-published triple combination raised IGF-1. Selected retrospective cohort; no isolated GHRP-6 effect or adequate safety comparison. Source: clinician-published. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Named on the 2026 list; prohibited in and out of competition.
- How long does a mixed vial last? Users refrigerate mixed vials; no validated home-vial storage duration was found.
Related to GHRP-6
- Ipamorelin: An experimental peptide that triggers growth hormone release.
- MK-677 (ibutamoren): This experimental oral drug raises growth hormone and IGF-1; risks include high blood sugar and swelling.
- GHRP-2: A peptide that releases growth hormone and can increase hunger.
- Hexarelin: A peptide that releases growth hormone; repeated use can weaken the response.
- Sermorelin: An experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Peptide products, Therapeutic Goods Administration · TGA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- GENOTROPIN® (somatropin) for injection, for subcutaneous use, FDA · 2025
- 注射用GHRP科研100, PMDA · 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2024
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline., Molitch ME et al. · The Journal of clinical endocrinology and metabolism · 2011
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.